Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Submitted by admin on October 2, 2023 - 10:14am
Source: 
Clinical Trials Arena
News Tags: 
Novartis
clinical trials
iptacopan
IgA nephropathy
kidney disease
Headline: 
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
snippet: 

Novartis unveiled positive top-line Phase III results for iptacopan in IgA nephropathy and plans talks with the FDA to obtain accelerated approval in 2024.

Do Not Allow Advertisers to Use My Personal information